INTRODUCTION
Chronic GVHD is a major source of morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT). Despite immune-suppressive prophylaxis, most survivors develop chronic GVHD. Among those with established chronic GVHD, primary therapy provides durable CR in the minority of cases, and secondary therapy is associated with poor response, infectious complications and mortality. Identification of biologic markers of the syndrome could facilitate significant advances in understanding to help guide prevention and treatment approaches. This review summarizes the literature in the field, with attention to consistent findings across studies as well as important divergent findings.
BIOLOGIC MARKERS ASSOCIATED WITH RISK FOR CHRONIC GVHD DEVELOPMENT
Donor-recipient non-HLA genetic polymorphism One major area of investigation has focused on polymorphisms in donor and/or recipient inflammatory and immunoregulatory cytokines. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] These largely demonstrate that polymorphisms in IL-1, IL-6, IL-10, and TNF-a are associated with increased risk of chronic GVHD. Other findings largely come from single gene candidate studies (Table 1) . 7, [14] [15] [16] [17] [18] [19] [20] [21] [22] Negative findings reported by Lin et al. 23 (IL-10 promoter genotype), Cullup et al. 4 (IL-10 polymorphism), Bertinetto et al.
1
(IL-1R antagonist (IL-1RA), IL-10, and IL-1b), Takahashi et al.
10
(donor-derived TNF2 allele (A)), Viel et al. 11 (IL-2) and Laguila et al.
6
(TNF-a, IFN-g, IL-10 or transforming growth factor (TGF)-b1) should be noted.
Together, these findings threaten confidence in associations between cytokine polymorphisms and chronic GVHD risk.
Immune cell populations Several studies have examined association of the cellular content of the donor allograft and risk of chronic GVHD (Table 2) . [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] While earlier studies have studied BM, more recent studies focus on PBSC grafts. These studies support an inverse association between donor allograft nucleated cell and CD34 þ (cluster of differentiation molecule 34 (hematopoietic progenitor cell Ag CD34)) cell dose, plasmacytoid DC, and natural killer (NK) cell dose and subsequent risk of chronic GVHD. Examination of immune reconstitution from the recipient peripheral blood post-HCT supports deficiency in regulatory cell populations, including NK and regulatory T cells (Treg), as a determinant of subsequent chronic GVHD (Table 2) .
Relevant negative findings include the following: Sierra et al. 34 found no association between marrow cell dose and risk of chronic GVHD. Baron et al. 35 reported no effect of CD34 þ dose in non-myeloablative conditioning and unrelated donor HCT. Li et al. 26 found no difference in CD4 þ (cluster of differentiation molecule 4 (T-cell surface glycoprotein CD4)) T cells or NK cells between those who subsequently developed chronic GVHD or not. The findings of Ukena et al. 36 challenge the inverse association of Treg and chronic GVHD risk: those who developed chronic GVHD had comparable or increased CD4 þ CD25 þ CD127 low (cluster of differentiation molecule 127 (IL-7 receptor)) Treg compared with those without chronic GVHD.
Inflammatory and immunoregulatory mediators
Prospective studies examining serial peripheral blood samples post-HCT support differences in inflammatory and immunoregulatory cytokines between those who do or do not develop chronic GVHD (Table 3) . 26, 31, [37] [38] [39] Chronic GVHD development is associated with increased TNF-a, IL-10 and B-cell activating factor (TNF (ligand) superfamily, member 13b) (BAFF), and decreased TGF-b and IL-15. Findings related to IFN-g are not consistent.
Predictors restricted to specific chronic GVHD phenotypic groups Inamoto et al. 18 found that CCR9 (chemokine (C-C motif) receptor 9) genotype 926AG was associated with increased risk for cutaneous chronic GVHD. Shimura et al. 40 demonstrated that CD34 þ CD133 þ (cluster of differentiation molecule 133 (prominin 1)) vascular endothelial growth factor À R2 endothelial progenitor cells remained low among those that developed sclerodermatous chronic GVHD. In addition, vascular endothelial growth factor and basic fibroblast growth factor differed among HCT recipients vs healthy controls, but no significant difference was observed between HCT recipients with or without sclerodermatous chronic GVHD. Mattsson et al. 41 demonstrated that low levels of clara cell secretory protein (CC16) predated diagnosis of bronchiolitis obliterans syndrome by median of 10 months. This is a notable finding, as there are few established clinical predictors of the syndrome, and decline in pulmonary function can pre-date clinical recognition. 
BIOLOGIC MARKERS ASSOCIATED WITH CHRONIC GVHD DIAGNOSIS
Immune cell populations Examination of immune cell subsets in chronic GVHD has largely focused on T-cell subsets: the evidence demonstrates that chronic GVHD is associated with increased CD3 þ (cluster of differentiation molecule 3 (T-cell co-receptor; CD3-T-cell receptor complex)) T cells, 42 Th17 (T helper 17 cells), 43 and both CD4 þ and CD8 þ (cluster of differentiation molecule 8 (T-cell co-receptor)) effector memory cells. 44, 45 Monocytes are increased, 46 and CD86 (cluster of differentiation molecule 86 (T-lymphocyte activation Ag CD86; B7-2 Ag)) expression is increased on monocytes and B cells (in response to CpG stimulation). 46, 47 In contrast, chronic GVHD is associated with a deficiency of Treg, 27, 43 NK cells 42 and naive CD8 þ T cells. 44 In one study, Treg (defined by forkhead box P3 (FoxP3) mRNA expression) were decreased, and T-cell receptor gene rearrangement excisional circles levels were reduced in chronic GVHD patients, suggesting that defective thymic function contributes to impaired Treg reconstitution. 27 Most investigation supports a reduction in total CD19 þ (cluster of differentiation molecule 19 (B-lymphocyte Ag CD19)) B cells, but divergent findings have been reported on B-cell subsets (naive, transitional and memory).
48-51 B-cell sub-populations may differ according to degree of humoral immunity impairment (Table 4) . 50 Recent data suggest that B cells in chronic GVHD patients have increased ERK and AKT signaling, and decreased levels of the pro-apoptotic Bim. 52 Relevant negative findings include the following: Clark et al. 53 reported that chronic GVHD patients had increased numbers of CD4 þ CD25 high T cells; while FoxP3 was not studied, these cells lacked markers of activation, expressed CTLA-4 and demonstrated suppressive activity of CD4 þ CD25 À T cells after polyclonal stimulus. Arpinati et al. 46 found that number and phenotype of BDCA1 þ (CD1c molecule (T-cell surface glycoprotein CD1c)) CD19
À myeloid and BDCA2 þ (C-type lectin domain family 4, member C (DC lectin b)) CD123 þ (cluster of differentiation molecule 123 (IL-3 receptor, alpha)) plasmacytoid DC in the peripheral blood were similar in those with or without chronic GVHD; this finding contradicts previous reports suggesting allograft DC content was a predictor of chronic GVHD. Finally, Greinix et al. 49 found no significant differences in absolute B-, Tand NK-cell numbers between those with and without chronic GVHD; this finding challenges relative consensus among other reports.
Inflammatory and immunoregulatory mediators
Most studies have examined biologic markers of chronic GVHD diagnosis without attention to the time of chronic GVHD onset and sample acquisition after HCT or matching cases to controls at comparable time post-HCT (Table 5) . 43, [54] [55] [56] [57] [58] The major exceptions to this are the reports from Fujii et al. 59 and Rozmus et al.
60
Another consideration is that most have examined a limited set of individual cytokines grounded in the Th1 (T helper 1 cells)/Th2 (T helper 2 cells) paradigm, rather than more comprehensive discovery-based investigation. Finally, the control groups studied in comparison with chronic GVHD cases differ. Acknowledging these considerations, most studies support increased pro-inflammatory cytokines in chronic GVHD cases, including TNF-a, IL-6, IL-1b, IL-8, soluble alpha chain of the IL-2 receptor shed by activated T cells (sIL-2R) and IL-1Ra, among others. Validated proteomic work from suggests that BAFF, sCD13 (soluble CD13 (aminopeptidase-N)), 61 elafin, IL-2Ra, MIG (chemokine (C-X-C motif) ligand 9, CXCL9) and anti-double stranded DNA Ab (anti-dsDNA) may distinguish chronic GVHD cases from nonchronic GVHD controls with high accuracy. 62 Work from Fujii et al. 59 and Rozmus et al. 60 suggests that diagnostic markers of chronic GVHD may differ according to the time of chronic GVHD onset. Fujii et al. reported that early-onset chronic GVHD had increased soluble B cell activating factor (sBAFF), anti-dsDNA, sIL-2Ra and sCD13. Late-onset chronic GVHD cases had increased sBAFF and anti-dsDNA. Rozmus et al. reported that earlyonset chronic GVHD demonstrated decreased IFN-g and IL-2, while late-onset chronic GVHD had decreased IL-4, IL-2 and FoxP3.
Few studies have tried to discern the impact of immune suppression treatment on observed findings between chronic GVHD and non-chronic GVHD groups, since patients with chronic GVHD are often treated with multiple immune-suppressive agents whereas patients without chronic GVHD may be off medications. A notable exception is the work from Kohrt et al. 63 , where specific analyses isolated and identified the effects of medications by comparing new onset chronic GVHD cases not on immune suppression and patients with chronic GVHD already on treatment.
Relevant negative findings include the following: Tanaka et al. 58 did not detect differences in IL-12 production between chronic GVHD and control subjects. As IL-12 is a major signal important for Th1 differentiation, Tanaka's results combined with multiple other conflicting findings challenge efforts to classify chronic GVHD as either a pure Th1 or Th2 disease. Fujii et al. 59 found that IFN-g and IL-6 did not significantly differ between early or late chronic GVHD and controls; this challenges other reports implicating IFN-g and IL-6. A number of important negative findings were reported by Rozmus et al. 60 There was no significant difference in IL-10 between early-or late-onset chronic GVHD and control; this challenges multiple reports implicating IL-10 in prediction and diagnosis of chronic GVHD. There was increased FoxP3 mRNA expression (P ¼ 0.08) in early-onset chronic GVHD, whereas FoxP3 expression was lower in late-onset chronic GVHD patients (P ¼ 0.04); this finding adds to the complexity of the relationship between FoxP3 expression (not exclusive to Treg) and chronic GVHD. There was no correlation between cytokine patterns and organ involvement by chronic GVHD, and there was no correlation between cytokine expression and immune cell subsets. However, Sarantopoulos et al.-BAFF levels, initially high within the first 3 months following HCT, declined among those who did not develop chronic GVHD. Conversely, those who developed chronic GVHD had persistently elevated BAFF levels, and 6-month BAFF levelsX10 ng/mL were significantly associated with development of chronic GVHD. In patients who subsequently developed chronic GVHD, there was persistent elevation in BAFF and CD27
þ B-cell subsets together with decreased numbers of naive B cells, resulting in a high BAFF:B-cell ratio.
it should be noted that the overall sample size in this analysis limits definitive conclusions.
Other markers Other diverse markers have been reported: Svegliati et al. 64 detected anti-PDGF receptor Abs in extensive chronic GVHD cases, but not in non-chronic GVHD cases or control subjects. Lai et al. 65 found that chronic GVHD patients had significant upregulation of CD28 (cluster of differentiation 28 (T-cell-specific surface glycoprotein CD28)) and phosphatidylinositol-4,5-bisphosphate 3 kinase compared with those without chronic GVHD. Kohrt et al. She et al.-newly diagnosed extensive chronic GVHD (treated on phase III trial of cyclosporine/prednisone vs cyclosporine/prednisone/hydroxychloroquine). Early-onset chronic GVHD cases were 3-to 8-month post-HCT, whereas late-onset cases wereX9-month post-HCT. Early chronic GVHD cases were matched to 6-month post-HCT control samples, and late-onset GVHD cases were matched to 12-month post-HCT control samples.
f Kuzmina et al.-patients with established (median duration of chronic GVHD was 42 months) chronic GVHD were studied to discern differences in B-cell sub-populations according to degree of humoral immunity impairment (serum Ig levels).
Chronic GVHD biomarkers J Pidala et al disintegrin and metalloproteinase with thrombospondin motifs 3), AREG (amphiregulin), DAP2IP (DOC-2/DAB2 interactive protein), IRS2 (insulin receptor substrate 2), CXCR7 (C-X-C chemokine receptor type 7) and CPM (carboxypeptidase M)) accurately distinguished chronic GVHD cases from controls. Boutin et al. 66 found that urinary collagen degradation markers were not different between chronic GVHD patients at onset before starting immune-suppressive therapy vs autologous HCT patients or normal controls. McGuirk et al. 20 demonstrated that serum haptoglobin levels in patients with chronic GVHD were higher than in patients without chronic GVHD and normal controls. Although these findings largely do not coalesce in a theoretical framework with the other reported findings to date, they speak to potential heterogeneous mechanisms involved in chronic GVHD, the importance of discovery-based approaches, and the need for further validation studies.
Diagnosis restricted to specific chronic GVHD phenotypes A small number of studies have examined biologic markers of certain organ manifestations: Westekemper et al. 67 found that expression of the Th1-associated chemokines-chemokine (C-X-C motif) ligand (CXCL9) (MIG), chemokine (C-X-C motif) ligand 10 (IP-10) and their receptor chemokine (C-X-C motif) receptor 3 (CXCR3)-were significantly increased in chronic GVHD conjunctival biopsies compared with controls. However, no correlation was found between chemokine expression levels and severity of clinical findings. Compared with HCT recipients without oral chronic GVHD, Imanguli et al. 68 found that patients with oral involvement had increased T-bet þ effector T cells, keratinocyte apoptosis, expression of CXCL9 (MIG) and CXCR3 , and type I IFN-mediated signaling events including signal transducer and activator of transcription 1 phosphorylation. Mattsson et al. 41 found that serum CC16 (clara cell secretory protein) levels were significantly lower in bronchiolitis obliterans syndrome, and Kuzmina et al. 69 has reported higher percentage of CD19 þ CD21 low (complement component (3d/Epstein Barr virus) receptor 2) B cells in newly diagnosed bronchiolitis obliterans syndrome.
BIOLOGIC MARKERS ASSOCIATED WITH CHRONIC GVHD SEVERITY
Relatively little information exists on the relationship between chronic GVHD severity and biologic markers of chronic GVHD. The majority have been described in the context of a historic classification schema (limited vs extensive disease): Barak et al. 54 described that TNF-a, IL-6, and IL-1b levels correlated with severity of established chronic GVHD. Miura et al. 27 found that FoxP3 expression inversely correlated with the extent of chronic GVHD. Li et al. 26 described that limited chronic GVHD had greater Treg, greater TGF-b and lower TNF-a compared with extensive chronic GVHD. Sarantopoulos et al. 38, 51 did not demonstrate significant difference in BAFF levels between limited and extensive chronic GVHD.
More recent reports, however, have utilized the proposed NIH Consensus classification for chronic GVHD severity: Kuzmina et al. 50 reported that those with severe chronic GVHD had significantly lower naive B cells and non-class-switched memory B cells compared with those with mild and moderate chronic GVHD. Imanguli et al. 68 demonstrated that caspase-3, CD8, CD3, CD68 (cluster of differentiation molecule 68 (macrophage Ag CD68)), KI-67 (MKI67 (proliferation-related Ki-67 Ag), IL-15, MxA (IFN-induced MxA GTPase) levels were positively associated with increasing clinical chronic GVHD severity.
BIOLOGIC MARKERS ASSOCIATED WITH CHRONIC GVHD PHENOTYPE
Fujii et al. 59 reported several correlations between studied biomarkers and sites of chronic GVHD organ involvement: Chronic GVHD biomarkers J Pidala et al hepatic involvement was associated with sBAFF and sCD13; ocular involvement was associated with anti-dsDNA and anticardiolipin Ab; joint involvement was associated with anti-dsDNA levels, sBAFF, IL-6 and monocyte chemoattractant protein 1; sclerodermatous involvement was associated with anti-dsDNA; and lichenoid skin rash was associated with sBAFF. Svegliati et al.
64
found that higher levels of anti-PDGF receptor Abs were detected in those with extensive skin or lung involvement. Kuzmina et al.
50
reported multiple associations among B-cell subsets and BAFF levels and chronic GVHD organ involvement: Those with ocular involvement had the lowest CD19 þ B-cell and highest transitional B-cell numbers; those with pulmonary involvement had lower total CD19
þ , elevated immature B cells, decreased naive B cells and non-class switched memory B cells, and elevated BAFF levels; scleroderma was associated with higher immature B cells, lower non-class-switched and class-switched memory B cells, and higher BAFF levels.
BIOLOGIC MARKERS ASSOCIATED WITH CHRONIC GVHD RESPONSE TO THERAPY Kobayashi et al. 55 reported that patients with response to chronic GVHD therapy had a decrease in sIL-2R levels. Fujii et al. 59 reported that responders had significantly lower sIL-2Ra at chronic GVHD diagnosis than non-responders. Change over time after initial therapy appeared to be relevant: the ratio of 2-month level to that at start of therapy was studied as predictor of 9-month response. A lower ratio of sBAFF was correlated (P ¼ 0.05) with response, while the other studied markers were not. Sarantopoulos et al. 70 reported that responders to anti-CD20 therapy demonstrated naive B-cell reconstitution and decreased BAFF/B-cell ratios. Dander et al. 43 reported limited data to support that IL-17-producing CD4 þ cells on ELISPOT assay were associated with change in acute and chronic GVHD activity; clinical progression associated with increase in Th17 cells, whereas decline in organ scores correlated with decrease in Th17 cells. Greinix et al. 49 demonstrated a decreased ratio of CD21 À immature/transitional B cells to CD27 þ (cluster of differentiation molecule 27 (CD 27 Ag)) memory B cells over time among those who achieved partial response (vs no response or progression) to chronic GVHD therapy.
BIOLOGIC MARKERS ASSOCIATED WITH PROGNOSIS FOLLOWING CHRONIC GVHD
Very few studies have demonstrated an association between biologic markers and survival. Pre-HCT polymorphism in mucosal addressin cell adhesion molecule-1 was associated with decreased OS.
14 In a small number of chronic GVHD cases, Kobayashi et al.
55
found that responders to therapy had a decrease in sIL-2R after therapy, whereas progressive increase in sIL-2R was associated with mortality. These minimal data are far from definitive, and much more investigation is needed in this domain.
CONCLUSIONS AND FUTURE DIRECTIONS
Major shortcomings in current practice and clinical investigation emphasize the potential importance of biologic markers of chronic GVHD. However, despite extensive investigation, there is little evidence that findings have facilitated a cohesive understanding, have translated into clinically useful tools, or have informed therapeutic strategies. We aim here to synthesize previously reported findings with attention to challenges in their interpretation, and to identify gap areas for future investigation. Validated markers for risk of chronic GVHD development may permit avoidance of donors prone to cause chronic GVHD or alteration of transplant or GVHD approaches to mitigate these risks. Although polymorphism in several cytokines appears to have importance, most are countered by other negative findings.
Further work is needed to understand the relative importance of these findings in the context of known and emerging data in the field of donor-recipient HLA matching, [71] [72] [73] [74] [75] [76] MHC haplotype single-nucleotide polymorphism, 77 and minor histocompatibility mismatch. [78] [79] [80] Published evidence supports deficiency of important regulatory cell populations (NK, Treg and DC2), and changes in post-HCT cytokines (increased TNF-a, IL-10 and BAFF, and decreased TGF-b) as markers of subsequent chronic GVHD development.
Diagnostic markers for chronic GVHD may have several practical applications, such as incorporation into current diagnostic criteria, distinguishing chronic from late acute GVHD, and identification of therapeutic targets. Current evidence supports that chronic GVHD is associated with increased CD3 þ T cells, Th17, CD4 þ and CD8 þ effector memory cells, monocytes, CD86 expression, and BAFF/Bcell ratio. In contrast, chronic GVHD is associated with a deficiency of Treg, NK cells and naive CD8 þ T cells. Evidence regarding specific B-cell subsets is conflicting across reports and requires further study. Inflammatory mediators including TNF-a, IL-6, IL-1b, IL-8, sIL-2R and IL-1Ra have been reported, but require validation. BAFF, anti-dsDNA, sIL-2Ra and sCD13 are supported by work from Fujii et al., and have been tested and validated (these together with also elafin and MIG) by Kitko et al. 62 These represent important candidates for further validation.
Validated markers for chronic GVHD severity and phenotype have great potential for several applications. However, investigation performed to date is limited, focused on limited individual candidates, and lacks validation. Dedicated work in this area, particularly in the era of NIH Consensus severity and phenotype classification is needed. The associations summarized in this review are preliminary and require validation in larger studies.
Biologic markers associated with response and prognosis following treatment for chronic GVHD could greatly augment current clinical practice. Rational therapy could target mechanisms of resistance. Validated early markers of non-response could be used to identify non-responders before they develop worsening clinical chronic GVHD. There has been little investigation in this area to date, and this represents a priority area for future research.
There are several major challenges to consider: first, there is heterogeneity in the chronic GVHD cases included in different studies. Most pre-date the NIH Consensus guidelines, and therefore likely include late acute GVHD. There has been little attention to the impact of chronic GVHD organ involvement and severity on the studied outcomes. Time from HCT to sample acquisition (and matching cases-controls for this variable), interval between chronic GVHD onset and sample collection, and degree and type of immune suppression likely also impact results. As well, the bulk of studies deal with peripheral blood markers. Although this represents a clinically feasible approach, biopsies at sites of chronic GVHD involvement may be important. The non-chronic GVHD controls in these studies also vary. Finally, most of the reported studies are small, have examined a limited number of candidates, conflict with other published results and lack validation; these challenges may explain major contradictory results in the existing literature.
Thus, the major challenge for future investigation in chronic GVHD biologic markers will be to perform adequately powered studies utilizing well-characterized clinical populations with attention to selection of chronic GVHD cases and controls, the impact of other clinical variables including immune suppression, and subsequent validation of findings. Translation of such findings should provide clinically useful tools for assessing risk for chronic GVHD and chronic GVHD therapeutic response, and identify novel therapeutic strategies.
